Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer

Centromere protein F (CENPF) is a protein associated with the centromere-kinetochore complex and chromosomal segregation during mitosis. Previous studies have demonstrated that the upregulation of CENPF may be used as a proliferation marker of malignant cell growth in tumors. The overexpression of C...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular medicine 2015-04, Vol.35 (4), p.966-972
Main Authors: ZHUO, YANG-JIA, XI, MING, WAN, YUE-PING, HUA, WEI, LIU, YUAN-LING, WAN, SONG, ZHOU, YU-LIN, LUO, HONG-WEI, WU, SHU-LIN, ZHONG, WEI-DE, WU, CHIN-LEE
Format: Article
Language:English
Subjects:
Age
Antigens
biochemical recurrence-free survival
Breast cancer
Cancer patients
Cancer therapies
Care and treatment
Cell cycle
Cell division
centromere protein F
Chemotherapy
Chromosomes
clinico pathological characteristic
Datasets
Diagnosis
Disease
Liver cancer
Medical prognosis
Metastasis
Mortality
Multivariate analysis
Prognosis
Prostate cancer
Proteins
Surgical outcomes
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Centromere protein F (CENPF) is a protein associated with the centromere-kinetochore complex and chromosomal segregation during mitosis. Previous studies have demonstrated that the upregulation of CENPF may be used as a proliferation marker of malignant cell growth in tumors. The overexpression of CENPF has also been reported to be associated with a poor prognosis in human cancers. However, the clinical significance of CENPF in prostate cancer (PCa) has not yet been fully elucidated. Thus, the aim of the present study was to determine the association of CENPF with tumor progression and prognosis in patients with PCa. The expression of CENPF at the protein level in human PCa and non-cancerous prostate tissues was detected by immunohistochemical analysis, which was further validated using a microarray-based dataset (NCBI GEO accession no: GSE21032) at the mRNA level. Subsequently, the association of CENPF expression with the clinicopathological characteristics of the patients with PCa was statistically analyzed. Immunohistochemistry and dataset analysis revealed that CENPF expression was significantly increased in the PCa tissues compared with the non-cancerous prostate tissues [immunoreactivity score (IRS): PCa, 177.98±94.096 vs. benign, 121.30±89.596, P
ISSN:1107-3756
1791-244X
DOI:10.3892/ijmm.2015.2086